A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3′- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer

3, 3′-diindolylmethane (DIM) modulates estrogen metabolism and acts as an anti-androgen which down-regulates the androgen receptor and prostate specific antigen (PSA). We conducted a dose-escalation, phase I study of BioResponse (BR)-DIM with objectives to determine the maximum tolerated dose (MTD),...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Heath, Elisabeth I, Heilbrun, Lance K, Li, Jing, Vaishampayan, Ulka, Harper, Felicity, Pemberton, Pam, Sarkar, Fazlul H
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: e-Century Publishing Corporation 2010
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2923864/
https://ncbi.nlm.nih.gov/pubmed/20733950
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia